Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9946543 | 1.00 | GLO1 (0.43) | GLO1ALDH1A1LMNAHSD17B10EP300 | |
| SCHEMBL5594111 | 1.00 | GLO1 (0.43) | GLO1ALDH1A1LMNAHSD17B10EP300 | |
| SCHEMBL1421463 | 0.88 | EP300 (0.37) | GLO1ALDH1A1LMNAHSD17B10EP300 | |
| SCHEMBL824578 | 0.88 | GLO1 (0.48) | GLO1ALDH1A1LMNAHSD17B10HCAR2 | |
| SCHEMBL23123466 | 0.87 | GLO1 (0.41) | GLO1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL23123465 | 0.87 | GLO1 (0.41) | GLO1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL8832097 | 0.82 | EP300 (0.33) | GLO1ALDH1A1EP300HCAR2CYP2D6 | |
| SCHEMBL6764899 | 0.80 | GLO1 (0.42) | GLO1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL6764901 | 0.80 | GLO1 (0.42) | GLO1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL5697356 | 0.80 | EP300 (0.32) | EP300HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118206533-A | N-pyridazine pyrazole amide compounds | 湖南化工研究院有限公司 | 2024-06-18 | — | — | CN | claimed |
| WO-2007086076-A2 | AN IMPROVED PROCESS FOR PREPARATION OF LEFLUNOMIDE | UNICHEM LABORATORIES LIMITED (IN) | 2007-08-02 | — | — | WO | claimed |
| WO-2024140356-A1 | CATHEPSIN L INHIBITORS | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024131893-A1 | IRE1α SMALL MOLECULE INHIBITORS | SHANGHAI YI ZHONG XING BIOTECHNOLOGY CO., LTD. (CN) | 2024-06-27 | — | — | WO | disclosed |
| CN-118206533-A | N-pyridazine pyrazole amide compounds | 湖南化工研究院有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240140915-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-05-02 | — | — | US | disclosed |
| US-20240067612-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| WO-2024010782-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| CN-116751200-A | Tricyclic compounds containing substituted pyridones and methods of using the same | 爱彼特生物制药公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116396221-A | Preparation method of 1- (3-hydroxy-3-methyl-2-butyl) -5-methyl-1H-pyrazole-4-carboxylic acid | 无锡科华生物科技有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-110114071-B | Tricyclic compounds containing substituted pyridones and methods of using the same | 爱彼特生物制药公司 | 2023-07-04 | — | — | CN | disclosed |
| WO-1986001202-A1 | PYRIDONE ESTERS AS INOTROPIC AGENTS | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1986-02-27 | — | — | WO | disclosed |
| EP-0112322-A1 | Enamine derivatives of phosphonic acid esters | MONSANTO COMPANY (US) | 1984-06-27 | — | — | EP | disclosed |
| EP-0112321-A1 | Enamine derivatives of phosphonic acid esters | MONSANTO COMPANY (US) | 1984-06-27 | — | — | EP | disclosed |
| US-4444582-A | Enamine derivatives of phosphonic acid esters as herbicides | MONSANTO COMPANY (US) | 1984-04-24 | — | — | US | disclosed |
| US-4444581-A | Enamine derivatives of phosphonic acid esters as herbicides | MONSANTO COMPANY (US) | 1984-04-24 | — | — | US | disclosed |
| US-4301186-A | FOR IN SITU DECOMPOSITION BY RADIATION TO PRODUCE AMINES FOR HARDENING A POLYURETHANE OR EPOXY RESIN MONOMERS SOLUTION | BAYER AKTIENGESELLSCHAFT (DE) | 1981-11-17 | — | — | US | disclosed |
| US-4087535-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-05-02 | — | — | US | disclosed |
| US-4061767-A | ANTIINFLAMMATORY, ANALGESIC | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-12-06 | — | — | US | disclosed |
| US-3987051-A | Method for producing 1-unsubstituted pyrazolo[3,4-b]pyridine ketones | E. R. SQUIBB & SONS, INC. (US) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067612-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | GLO1 1439/4885ALDH1A1 2371/4885LMNA 372/4885 |
| US-20240140915-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | GLO1 1439/4885ALDH1A1 2371/4885LMNA 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.